Navigation Links
Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
Date:2/15/2008

lipid improvements beyond simvastatin 20-mg treated baseline, with additional LDL reductions of 12 percent and an additional 21 percent HDL increase compared to a 7 percent decrease in LDL and an 8 percent increase in HDL with simvastatin 20mg alone. Furthermore, SIMCOR reduced triglycerides by an additional 27 percent compared to 15 percent with simvastatin 20mg alone.

SIMCOR was generally well tolerated by patients in clinical studies. Six percent of patients discontinued therapy due to flushing, the most commonly reported side effect of SIMCOR and niacin-based therapies. Flushing can be minimized by taking aspirin or an NSAID 30 minutes prior to taking the medication at bedtime. Flushing may subside over several weeks of consistent SIMCOR use.

"With SIMCOR, doctors now have a new option for helping patients reach their LDL and HDL cholesterol treatment goals with a combination of two proven therapies," said Eugene Sun, M.D., vice president of Global Clinical Development for Abbott. "Abbott is committed to bringing forward new cholesterol therapies, and SIMCOR represents a new treatment option for patients in Abbott's rapidly expanding portfolio of cholesterol treatments for lipid disorders."

The American Heart Association, National Cholesterol Education Program (NCEP) and American College of Cardiology recommend more aggressive treatment of HDL to reduce cardiovascular risk. Cholesterol and other lipids can build up in the bloodstream forming plaque and restricting blood flow, which can lead to heart disease. According to NCEP guidelines, a reduction in LDL of 1 percent is associated with a 1 percent reduction in heart disease risk. Additionally, raising HDL by 1 point is associated with a 2 percent heart disease risk reduction.

Abbott is committed to the continued research of its products and has sponsored the National Heart Lung and Blood Institute's AIM-HIGH outcomes study. The study is designed to evaluate the effects of niacin ext
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Abbott Named One of the Best Places to Launch a Career by BusinessWeek
2. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
3. Abbott Scientists Create One Molecule With Two Antibody Functions
4. Abbott Named to Science Magazines List of Top Employers in the Biotech and Pharmaceutical Industry
5. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
6. Abbott Declares 336th Consecutive Quarterly Dividend
7. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
8. Abbott to Present at JP Morgan Healthcare Conference
9. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
10. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, April ... Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... nonprofit organization solely dedicated to finding a cure for hepatitis ... worldwide, will host its annual Crystal Ball on Friday, April ...
(Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... ViroPharma Incorporated (Nasdaq: VPHM ) today announced that ... investment conferences. , Vincent Milano, president and chief ... 20th Annual Healthcare Conference at 4:30 P.M. EST on ... held at the Waldorf=Astoria in New York City. , ...
... 50/50 joint venture agreement signed with Hunan, Biopharmaceutical ... manufacturing facility, - Biologics: 23% growth in sales and to ... of KINLYTIC(TM) thrombolytic, agent for pulmonary embolism, ... under, agreement, - Dr. Mark ...
... DNDN ) today announced that management will present at the following upcoming ... New York City, Tuesday, November 10, 2009, ... Phoenix, Arizona, Friday, November 13, 2009, ... Conference, New York City, Tuesday, November 17, ...
Cached Biology Technology:ViroPharma to Present at Three November Healthcare Conferences 2Microbix Biosystems Provides a Corporate Update 2Microbix Biosystems Provides a Corporate Update 3Microbix Biosystems Provides a Corporate Update 4Microbix Biosystems Provides a Corporate Update 5Microbix Biosystems Provides a Corporate Update 6Microbix Biosystems Provides a Corporate Update 7
(Date:4/20/2014)... analysis growing in importance for both basic researchers ... and the University of Maryland have developed a ... of gene activity from RNA sequencing (RNA-seq) data., ... famously speedy fish, estimates of gene expression that ... a few minutes, with accuracy that equals or ...
(Date:4/20/2014)... Although doctors have long known that people with Down ... leukemia (ALL) during childhood, they haven,t been able to ... Institute investigators has uncovered a connection between the two ... the journal Nature Genetics , the researchers track ... abnormality in Down syndrome to the cellular havoc that ...
(Date:4/18/2014)... techniques like X-ray crystallography and nuclear magnetic resonance imaging ... of molecules, but such efforts have long been hampered ... a specific molecule and often in ordered and crystalized ... impossible to peer into the structure of most molecules. ... be a thing of the past. , A ...
Breaking Biology News(10 mins):Computational method dramatically speeds up estimates of gene expression 2Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3MRI, on a molecular scale 2MRI, on a molecular scale 3
... voices, but now helium is also helping people with ... the University of Alberta in Edmonton, Canada have discovered ... allowed patients with chronic obstructive pulmonary disease (COPD) to ... per cent. COPD is a disease of the lungs ...
... For the first time in humans, scientists have found ... injuries caused by repetitive motion. , Their findings ... debilitating conditions such as carpal tunnel syndrome and tendonitis. ... researchers Ann Barr and Mary Barbe and their doctoral ...
... Two researchers from the University Hospital and the Center ... Navarra have published an article in Nature Cancer ... the area of cancer studies. The article, written by ... from the United States and Great Britain, addresses the ...
Cached Biology News:Helium helps patients breathe easier 2Red flag for repetitive stress injuries identified for first time in humans 2Researchers from the University of Navarra analyze new kinds of cancer-fighting antibodies 2